Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $47.6 million.

  • Ironwood Pharmaceuticals' Net Cash Flow rose 37524.15% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.9 million, marking a year-over-year increase of 32833.51%. This contributed to the annual value of -$3.6 million for FY2024, which is 9937.02% up from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Net Cash Flow is $47.6 million, which was up 37524.15% from -$15.0 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Net Cash Flow's 5-year high stood at $84.1 million during Q1 2023, with a 5-year trough of -$565.5 million in Q2 2023.
  • In the last 5 years, Ironwood Pharmaceuticals' Net Cash Flow had a median value of $19.9 million in 2025 and averaged -$11.8 million.
  • Data for Ironwood Pharmaceuticals' Net Cash Flow shows a peak YoY increase of 41444.43% (in 2023) and a maximum YoY decrease of 53530.32% (in 2023) over the last 5 years.
  • Ironwood Pharmaceuticals' Net Cash Flow (Quarter) stood at $45.9 million in 2021, then surged by 78.87% to $82.0 million in 2022, then tumbled by 123.48% to -$19.3 million in 2023, then skyrocketed by 101.7% to $327000.0 in 2024, then skyrocketed by 14450.76% to $47.6 million in 2025.
  • Its Net Cash Flow was $47.6 million in Q3 2025, compared to -$15.0 million in Q2 2025 and $19.9 million in Q1 2025.